MNOV, US58468P2065

MediciNova stock gained 9.20 percent after mixed Phase 2 data

Published on 10/05/2026 at 22:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MediciNova stock closed at USD 1.780 on October 2, 2026, after mixed tipelukast data. Four analysts rate it Strong Buy with an USD 8.25 target.

MNOV, US58468P2065, Illustration mit AI erstellt.

MediciNova stock (ISIN US58468P2065) closed at USD 1.780 on Nasdaq on October 2, 2026, gaining 9.20 percent as investors assessed mixed Phase 2 results for tipelukast. The September 28, 2026 study update showed meaningful improvements in several lipid measures, while the primary 24-week triglyceride comparison remained statistically non-significant.

Tipelukast delivers mixed data

According to GlobeNewswire on September 28, 2026, the randomized MN-001-NATG-202 trial enrolled 40 patients and lasted 24 weeks. At Week 4, triglycerides fell 54.7 mg/dL with MN-001 versus 23.8 mg/dL with placebo, a difference of 30.96 mg/dL with a p-value of 0.015.

The longer-term result was less decisive. At Week 24, triglycerides declined 45.8 mg/dL in the MN-001 group versus 14.4 mg/dL with placebo, but the 31.4 mg/dL gap carried a p-value of 0.113. HDL-C increased 3.3 mg/dL with treatment and declined 2.4 mg/dL with placebo, while HDL-P rose 3.62 micromoles per liter versus a 0.9 micromole decline.

Analysts keep bullish targets

According to Stock Analysis updated September 30, 2026, four analysts give MediciNova a Strong Buy consensus. Their average 12-month price target is USD 8.25, with a USD 6.00 low and USD 11.00 high, placing the average target 363.48 percent above the October 2 closing price.

The latest listed actions include H.C. Wainwright maintaining a Buy rating and a USD 10.00 target on September 29, 2026, and Maxim Group maintaining Buy with a USD 6.00 target on September 30, 2026, according to Stock Analysis. The gap between the optimistic targets and the mixed Week 24 data leaves future trial execution as the central valuation issue.

ALS results remain the next catalyst

MediciNova's other major program is the Phase 2b/3 COMBAT-ALS trial of MN-166. MediciNova said on September 24, 2026, that 234 participants had been randomized and that topline results from the double-blind portion were expected by the end of 2026. The full study's last patient, last visit is expected in March 2027.

Small-cap valuation stays sensitive

MediciNova reported USD 458,439 in revenue and a diluted GAAP loss of USD 0.05 per share for Q2 2026, compared with USD 186,984 in revenue and a USD 0.05 diluted GAAP loss in Q1 2026. Cash and cash equivalents stood at USD 25.4 million on June 30, 2026, while operating cash flow was negative USD 1.9 million in the quarter.

MediciNova stock closed at USD 1.780 on Nasdaq on October 2, 2026. Its 52-week range was USD 1.168 to USD 3.900, volume was 275,010 shares, and market capitalization was USD 87.6 million.